Insider · CIK 0001380178

Malik Shahzad

Reports to the SEC for 7 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001380178

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2021-06-17	Acutus Medical, Inc.A Award	Director	AAward	+1,800 sh	—	—	4,022
2021-06-17	Acutus Medical, Inc.Stock Options (Right to Buy)A Award	Director	AAward	+7,022 sh	—	—	7,022
2020-08-10	Acutus Medical, Inc.C Conversion	Director	CConversion	+65.4K sh	—	—	65,436
2020-08-10	Acutus Medical, Inc.C Conversion	Director	CConversion	+1.55M sh	—	—	1,551,713
2020-08-10	Acutus Medical, Inc.Series A Convertible Preferred StockC Conversion	Director	CConversion	−10.7K sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series A Convertible Preferred StockC Conversion	Director	CConversion	−254K sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series B Convertible Preferred StockC Conversion	Director	CConversion	−34.3K sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series B Convertible Preferred StockC Conversion	Director	CConversion	−813K sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series C Convertible Preferred StockC Conversion	Director	CConversion	−13.2K sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series C Convertible Preferred StockC Conversion	Director	CConversion	−313K sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series D Convertible Preferred StockC Conversion	Director	CConversion	−7,242 sh	—	—	0
2020-08-10	Acutus Medical, Inc.Series D Convertible Preferred StockC Conversion	Director	CConversion	−172K sh	—	—	0
2020-08-05	Acutus Medical, Inc.A Award	Director	AAward	+2,222 sh	—	—	2,222
2020-08-05	Acutus Medical, Inc.Stock Options (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,454
2020-01-21	ITRMIterum Therapeutics plc · 6.500% Exchangeable Senior Subordinated Note due 2025A Award	Director	AAward	—	$53000.00	—	—
2020-01-21	ITRMIterum Therapeutics plc · 6.500% Exchangeable Senior Subordinated Note due 2025A Award	Director	AAward	—	$1495000.00	—	—
2019-09-12	Aravive, Inc.Stock OptionA Award	Director	AAward	+7,500 sh	—	—	7,500
2019-06-13	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+19.7K sh	—	—	19,671
2019-01-03	Aravive, Inc.Stock OptionA Award	Director	AAward	+4,688 sh	—	—	4,688
2019-01-03	Aravive, Inc.Stock OptionA Award	Director	AAward	+4,688 sh	—	—	4,688
2018-12-06	Axonics, Inc.A Award	Director	AAward	+2,500 sh	—	—	2,500
2018-12-06	Axonics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2018-11-02	Axonics, Inc.C Conversion	Director	CConversion	+43.8K sh	—	—	43,822
2018-11-02	Axonics, Inc.C Conversion	Director	CConversion	+1.23M sh	—	—	1,275,000
2018-11-02	Axonics, Inc.C Conversion	Director	CConversion	+14.4K sh	—	—	1,289,412
2018-11-02	Axonics, Inc.C Conversion	Director	CConversion	+405K sh	—	—	1,694,349
2018-11-02	Axonics, Inc.Series B-2 Preferred StockC Conversion	Director	CConversion	−36.5K sh	—	—	0
2018-11-02	Axonics, Inc.Series B-2 Preferred StockC Conversion	Director	CConversion	−1.03M sh	—	—	0
2018-11-02	Axonics, Inc.Series C Preferred StockC Conversion	Director	CConversion	−12K sh	—	—	0
2018-11-02	Axonics, Inc.Series C Preferred StockC Conversion	Director	CConversion	−337K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+13.9K sh	—	—	13,921
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+7,771 sh	—	—	21,692
2018-05-30	ITRMIterum Therapeutics plcP Purchase	Director	PPurchase	+8,144 sh	$13.00	+$106K	29,836
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+391K sh	—	—	391,147
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+218K sh	—	—	609,485
2018-05-30	ITRMIterum Therapeutics plcP Purchase	Director	PPurchase	+229K sh	$13.00	+$2.97M	838,325
2018-05-30	ITRMIterum Therapeutics plc · Series B-1 Preferred SharesC Conversion	Director	CConversion	−13.9K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-2 Preferred SharesC Conversion	Director	CConversion	−7,771 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-1 Preferred SharesC Conversion	Director	CConversion	−391K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-2 Preferred SharesC Conversion	Director	CConversion	−218K sh	—	—	0
2018-05-24	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+11.2K sh	—	—	11,241
2017-12-20	Aravive, Inc.A Award	Director	AAward	+11.2K sh	—	—	23,880
2017-05-25	Aravive, Inc.A Award	Director	AAward	+3,480 sh	—	—	12,680
2017-05-25	Aravive, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+6,850 sh	—	—	6,850
2017-03-17	Aravive, Inc.S Sale	Director	SSale	−386K sh	$18.01	−$6.96M	1,621,558
2017-03-16	Aravive, Inc.S Sale	Director	SSale	−97.3K sh	$18.50	−$1.8M	2,007,925
2017-03-15	Aravive, Inc.S Sale	Director	SSale	−103K sh	$19.08	−$1.97M	2,105,228
2017-03-14	Aravive, Inc.S Sale	Director	SSale	−100 sh	$19.03	−$1,903	2,255,128
2017-03-14	Aravive, Inc.S Sale	Director	SSale	−46.8K sh	$19.00	−$889K	2,208,350
2017-03-13	Aravive, Inc.S Sale	Director	SSale	−16.3K sh	$19.42	−$317K	2,255,228

Recent filings

Accepted (ET)
Jun 224
Malik Shahzad0000950103-21-009179
SEC(opens sec.gov)
Aug 124
Malik Shahzad0000950103-20-015723
SEC(opens sec.gov)
Aug 74
Malik Shahzad0000950103-20-015478
SEC(opens sec.gov)
Jan 234
Malik Shahzad0000899243-20-001844
SEC(opens sec.gov)
Sep 134
Malik Shahzad0000899243-19-023556
SEC(opens sec.gov)
Jun 174
Malik Shahzad0000899243-19-017203
SEC(opens sec.gov)
Jan 74/A
Malik Shahzad0001213900-19-000325
SEC(opens sec.gov)
Jan 74
Malik Shahzad0001213900-19-000316
SEC(opens sec.gov)

Companies

Address

C/O CONATUS PHARMACEUTICALS INC. 4365 EXECUTIVE DRIVE, SUITE 200

SAN DIEGO, CA, 92121